Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00457275 |
To evaluate the LDL-C lowering in south african patients with primary hypercholesterolaemia after the addition of ezetimibe 10mg /day to ongoing therapy with a statin.
Condition | Intervention | Phase |
---|---|---|
Hypercholesterolemia |
Drug: MK0653, ezetimibe / Duration of Treatment: 4 Weeks |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicentre, Open-Label, Observational Local Study to Evaluate the LDL-C Lowering Effect of Ezetimibe as Prescribed in Daily Routine Practice in the South African Population |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_012 |
Study First Received: | April 5, 2007 |
Last Updated: | April 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00457275 History of Changes |
Health Authority: | South Africa: Medicines Control Council |
Antimetabolites Metabolic Diseases Hyperlipidemias Antilipemic Agents Ezetimibe |
Anticholesteremic Agents Metabolic Disorder Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Metabolic Diseases Hyperlipidemias Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Ezetimibe Anticholesteremic Agents Hypercholesterolemia Pharmacologic Actions Dyslipidemias Lipid Metabolism Disorders |